Search research articles
Contact Us
Filters
Showing results (651-660 of 657) with videos related to
Page
of 66
Sort By:
You have reached the last page of results.
This site can display upto 657 results.
Nature Medicine
|
October 7, 2018
Publisher Correction: Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma
David F McDermott, Mahrukh A Huseni, Michael B Atkins, et al.
Journal of Medical Genetics
|
December 7, 2014
Neuropathy target esterase impairments cause Oliver-McFarlane and Laurence-Moon syndromes
Robert B Hufnagel, Gavin Arno, Nichole D Hein, et al.
Circulation. Genomic and Precision Medicine
|
August 29, 2019
Biallelic Variants in <i>ASNA1</i>, Encoding a Cytosolic Targeting Factor of Tail-Anchored Proteins, Cause Rapidly Progressive Pediatric Cardiomyopathy
Judith M A Verhagen, Myrthe van den Born, Herma C van der Linde, et al.
Nature Medicine
|
June 6, 2018
Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma
David F McDermott, Mahrukh A Huseni, Michael B Atkins, et al.
Cell Reports. Medicine
|
January 4, 2023
CD8<sup>+</sup> T cell-intrinsic IL-6 signaling promotes resistance to anti-PD-L1 immunotherapy
Mahrukh A Huseni, Lifen Wang, Joanna E Klementowicz, et al.
Lancet (London, England)
|
December 13, 2016
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
Arjun V Balar, Matthew D Galsky, Jonathan E Rosenberg, et al.
Nature
|
February 15, 2018
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
Sanjeev Mariathasan, Shannon J Turley, Dorothee Nickles, et al.
Page
of 66
Search research articles
Search
Showing results (651-660 of 657) with videos related to
Sort By:
Page
of 66
You have reached the last page of results.
This site can display upto 657 results.
Nature Medicine
|
October 7, 2018
Publisher Correction: Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma
David F McDermott, Mahrukh A Huseni, Michael B Atkins, et al.
Journal of Medical Genetics
|
December 7, 2014
Neuropathy target esterase impairments cause Oliver-McFarlane and Laurence-Moon syndromes
Robert B Hufnagel, Gavin Arno, Nichole D Hein, et al.
Circulation. Genomic and Precision Medicine
|
August 29, 2019
Biallelic Variants in <i>ASNA1</i>, Encoding a Cytosolic Targeting Factor of Tail-Anchored Proteins, Cause Rapidly Progressive Pediatric Cardiomyopathy
Judith M A Verhagen, Myrthe van den Born, Herma C van der Linde, et al.
Nature Medicine
|
June 6, 2018
Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma
David F McDermott, Mahrukh A Huseni, Michael B Atkins, et al.
Cell Reports. Medicine
|
January 4, 2023
CD8<sup>+</sup> T cell-intrinsic IL-6 signaling promotes resistance to anti-PD-L1 immunotherapy
Mahrukh A Huseni, Lifen Wang, Joanna E Klementowicz, et al.
Lancet (London, England)
|
December 13, 2016
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
Arjun V Balar, Matthew D Galsky, Jonathan E Rosenberg, et al.
Nature
|
February 15, 2018
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
Sanjeev Mariathasan, Shannon J Turley, Dorothee Nickles, et al.
Page
of 66